ESR1 and breast cancer: As a game changer in ER positive advanced breast cancer, the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib, are currently treated for patients with ER positive and HER2 breast cancer [38].